Last reviewed · How we verify
NCT03988517
Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan
NA trial testing timing of receiving the drug in Hypothyroidism in 106 participants. Completed in 8 January 2018.
8 January 2018
Quick facts
| Lead sponsor | Hamad Medical Corporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 1 February 2017 |
| Primary completion | 8 January 2018 |
| Estimated completion | 8 January 2018 |
| Sites | 1 location across Qatar |
Drugs / interventions tested
- timing of receiving the drug
Conditions studied
- Hypothyroidism — all drugs for Hypothyroidism →
Sponsor
Hamad Medical Corporation — full company profile →
Who can join
Adults 18 to 70, any sex, with Hypothyroidism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Muslims all over the world fast during the month of Ramadan from dawn until dusk. There is little data regarding the best timing of levothyroxine intake during the month of Ramadan where taking it on an empty stomach represents a challenge to most patients.This study aims to compare two-time points of levothyroxine intake during Ramadan in terms of change in thyroid stimulating hormone (TSH), compliance and convenience.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03988517
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypothyroidism
Currently open trials in the same condition.
- NCT07060118 — Gluten Free Diet in Hashimoto's Hypothyroidism · NA · recruiting
- NCT06757712 — Periodization Resistance Training on Quality of Life in Females With Hypothyroidism · NA · recruiting
- NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism · Phase 2, PHASE3 · recruiting
- NCT06826248 — Clinical Efficacy of Darqeen Capsule for the Management of Hypothyroidism Associated with Female Reproductive Hormonal I · EARLY_PHASE1 · active not recruiting
- NCT07421869 — SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial · NA · recruiting
Other Hamad Medical Corporation trials
Trials by the same sponsor.
- NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
- NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
- NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
- NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
- NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03988517 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
- Last refreshed: 19 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988517.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing